NEW YORK (GenomeWeb News) – Veridex announced this week a deal with Laboratory Corporation of America to make its CellSearch circulating tumor cell test available in China.

LabCorp's Beijing central laboratory is now the first clinical reference laboratory in the country to offer CTC testing and will offer the test to researchers conducting clinical trials.

The agreement follows regulatory approval in China last month for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.